Cytox to present research on polygenic risk score application to stratification of risk for Alzheimer’s Disease at 13th International Conference on Genomics in Shenzhen, China.
Cytox CEO Richard Pither will deliver a presentation in the Personalized Medicine session at the International Conference on Genomics in Shenzhen, China on October 26th from 9:50am to 12:00pm. The session is chaired by Dr. Aristides A.N. Patrinos and will be held at the Shenzhen Marriott Hotel Golden Bay. The title of the presentation is, “Polygenic risk score application to the stratification of risk for Alzheimer’s Disease in early and pre-symptomatic individuals.” Additional conference details are available at www.icg-13.org
The development of effective new drugs for the treatment of late-onset Alzheimer's Disease (LOAD) has been hampered by a lack of understanding of the complex genetics and corresponding precision medicine strategies. This situation is now changing due in part to the application of polygenic risk score algorithms and pathway analysis, whereby risk for the future development of LOAD can be assessed in the early, pre-symptomatic stages of disease. A polygenic score is a number based on variation in multiple genetic loci and their associated weights and it serves as the best prediction for the trait that can be made when considering variation in multiple genetic variants. Polygenic scores, in conjunction with pathway analysis, promise to open a new era in the way that treatments are developed, people are screened, and therapies are prescribed for the most prevalent neurological diseases, including Alzheimer’s Disease.